Close Menu

NEW YORK – While Illumina has taken a hit to revenues due to the COVID-19 pandemic, the firm sees an expanded total addressable market in the new coronavirus normal.

"If you had talked to us in January, or certainly by December or before, we really would have talked to you much more about the clinical opportunity in oncology and reproductive health, but not a lot about infectious disease," Illumina CEO Francis deSouza told investors on a Thursday conference call following the release of the firm's second quarter financial results.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Sep
30
Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Oct
27
Sponsored by
LGC SeraCare Life Sciences

This webinar brings together an expert panel of stakeholders in cancer diagnostics and clinical care who will discuss the promise and challenges of liquid biopsy technologies in cancer diagnosis, monitoring, and patient care management.